Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
The Oncologist|November 19, 2020
Molecular Profiling of Exceptional Responders to Cancer TherapyMarijo Bilusic, Daniel Girardi, Yan Zhou, et al.
Cancer Research Communications|June 29, 2022
Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem CellsAustin T K Hoke, Michelle R Padget, Kellsye P Fabian, et al.
Clinical Genitourinary Cancer|June 12, 2021
Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair MutationsVincent Chau, Ravi A Madan, Marijo Bilusic, et al.
Cancer Immunology, Immunotherapy : CII|December 12, 2013
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinomaMarijo Bilusic, Christopher R Heery, Philip M Arlen, et al.
Frontiers in Endocrinology|August 28, 2020
A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid CancerJaydira Del Rivero, Renee N Donahue, Jennifer L Marté, et al.
Journal of Oncology Practice|June 23, 2016
Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With CancerCaitlin R Meeker, Daniel M Geynisman, Brian L Egleston, et al.
Clinical Genitourinary Cancer|December 20, 2016
Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective ReviewKyungsuk Jung, Pooja Ghatalia, Samuel Litwin, et al.
The Prostate|February 23, 2026
Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker InvestigationAlireza Abdshah, Mohammad Alyamani, Robert A Burgess, et al.
Journal for Immunotherapy of Cancer|September 7, 2019
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumorsMarijo Bilusic, Christopher R Heery, Julie M Collins, et al.
Prostate Cancer and Prostatic Diseases|January 26, 2022
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)Marijo Bilusic, Nicole J Toney, Renee N Donahue, et al.
Pageof 7